When people finish treatment for cancer, they want to bounce back to their former vital selves as quickly as possible. But a new Northwestern Medicine study - one of the largest survivor studies ever conducted - shows many survivors still suffer moderate to severe problems with pain, fatigue, sleep, memory and concentration three to five years after treatment has ended...
Vaccine Extends Recurrent GBM Survival Rates By 2 To 3 Times
6/05/2011
In data presented at The American Society of Clinical Oncology (ASCO) Annual Meeting, cancer researchers found that the brain tumor vaccine HSPPC-96 for treating recurrent gliobastoma (GBM) has a favorable safety profile and extends survival by two to three times more than the current median survival rate...
No Tie Found Between PTEN And Response To Breast Cancer Drug
6/05/2011
Contrary to what many oncologists had thought, a tumor suppressor protein known as PTEN does not reduce the effectiveness of the breast cancer drug Herceptin, according to a study by Mayo Clinic and North Central Cancer Research Group (NCCTG) investigators...
Erbitux Increased Overall Survival By 5.1 Months In Those With MCRC That Has Spread Beyond The Liver
6/05/2011
In alignment with this year's American Society of Clinical Oncology (ASCO) Annual Meeting theme, 'Patients, Pathways, Progress', Merck Serono, a division of Merck KGaA, Darmstadt, Germany, today announced the presentation of a retrospective analysis of the CRYSTAL trial demonstrating that Erbitux® (cetuximab) significantly improves outcomes in metastatic colorectal cancer (...
Sanofi announced today results of the pivotal SAVE-ONCO study which demonstrated that, in cancer patients initiating a chemotherapy regimen, investigational semuloparin significantly reduced the risk of the composite of symptomatic-deep vein thromboembolism (DVT), non-fatal pulmonary embolism (PE) or venous thromboembolism (VTE)-related death by 64%[i], meeting the study prima...
Survival Rates For Metastatic Melanoma Improve With Immune-boosting Interleukin-2 Vaccine
6/05/2011
For patients with advanced melanoma, which is the most lethal type of skin cancer, the results of a large clinical trial show that a vaccine combined with the immune-boosting drug Interleukin-2 can improve response rate and progression-free survival. The findings of the study were published in the June 2 issue of New England Journal of Medicine...
Talactoferrin Benefits Broad Range Of Lung Cancer Patients
6/04/2011
The investigational immunomodulatory agent talactoferrin boosts survival compared to placebo in multiple prognostically important subsets of patients with non-small cell lung cancer (NSCLC) who have failed first- or second-line therapy, according to phase II data released at the 2011 American Society of Clinical Oncology (ASCO) meeting. P. M...
Aromasin (exemestane) Reduces Breast Cancer Risk In Postmenopausal Women, Study
6/04/2011
Exemestane (Aromasin), an aromatase inhibitor, was found to lower invasive breast cancer rates by 65% in moderate and high-risk postmenopausal females, researchers at the Massachusetts General Hospital Cancer Center in Boston reported. An aromatase inhibitor inhibits aromatase, an enzyme involved in the production of estrogen estradiol. Many breast cancers are promoted by estrogens...
Study Identifies Genetic Mutations Associated With Cancer Risk For Hereditary Cancer Syndrome
6/04/2011
Among various genetic mutations for individuals with Lynch syndrome, a hereditary cancer syndrome that carries a high risk of colon cancer and an above-normal risk of other cancers, researchers have identified mutations associated with a lower cancer risk and mutations associateded with an increased risk for ovarian and endometrial cancer, according to a study in the June 8 iss...
An analysis of data from previously published studies indicates that longer time to beginning adjuvant chemotherapy after surgery for colorectal cancer is associated with worse survival, according to a study in the June 8 issue of JAMA, a theme issue on cancer...